A few times a year, KPMP sends letters to our enrolled participants to update them about study progress. Below is the Spring/Summer 2021 letter.
At KPMP, we describe participants like you as “our KPMP heroes.” Your participation continuous to be crucial to the success of this research. It’s been six months since we last updated you on KPMP’s progress. Here are some of the ways that our heroes are making an impact.
We reached a significant milestone. So far, 100 people have agreed to participate in KPMP. We completed over 90 biopsies. We recently began enrolling kidney donors and patients with kidney stones into our Indianapolis and Cincinnati enrollment sites. Tissue from these biopsies is being studied all over the country.
We are already learning from the biopsies that we have studied.
KPMP recently published an article about the purpose and importance of the study in the March 1st edition of Kidney International. The article, entitled Rationale and design of the Kidney Precision Medicine Project, describes the aims of our study, and how we hope people with kidney disease will benefit from this project. Members of the KPMP Community Engagement Committee, including kidney patients, wrote an article for CJASN about the importance of community engagement in KPMP: Integrating Patient Priorities with Science by Community Engagement in the Kidney Precision Medicine Project.
Please share these papers with your family and friends. If they want to learn more about KPMP, give them this link to the KPMP Introduction video.
Though the US continues to be impacted by COVID-19, all recruitment sites are safely enrolling study participants, performing biopsies and conducting follow up visits. KPMP has added an additional study to research how COVID-19infections may affect kidney function in the general population, as well as, in people living with kidney disease.
Your contribution to KPMP has had a significant impact. The KPMP could not exist without volunteers, like you, who have undergone a kidney biopsy. Thank you. Please contact us if you have any questions or comments.